The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Immunology of human fibrosis
Abstract
Fibrosis, defined by the excess deposition of structural and matricellular proteins in the extracellular space, underlies tissue dysfunction in multiple chronic diseases. Approved antifibrotics have proven modest in efficacy, and the immune compartment remains, for the most part, an untapped therapeutic opportunity. Recent single-cell analyses have interrogated human fibrotic tissues, including immune cells. These studies have revealed a conserved profile of scar-associated macrophages, which localize to the fibrotic niche and interact with mesenchymal cells that produce pathological extracellular matrix. Here we review recent advances in the understanding of the fibrotic microenvironment in human diseases, with a focus on immune cell profiles and functional immune-stromal interactions. We also discuss the key role of the immune system in mediating fibrosis regression and highlight avenues for future study to elucidate potential approaches to targeting inflammatory cells in fibrotic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Macrophages also recruit fibroblasts to form fibrotic microenvironment 10 and produce profibrotic factors to promote fibrosis 11.”
From Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice (2024) · cites this paper as [10]
In the citing paper
“The fibrogenic response is governed by the release of inflammatory mediators from innate, adaptive, and innate-like lymphoid cells and from nonprofessional immune cells (i.e., epithelial cells, hepatic myofibroblasts, and liver sinusoidal endothelial cells).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [11]
In the citing paper
“Upon removal of the underlying cause, liver fibrosis can resolve via activation of specific immune cell subsets.”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [11]
In the citing paper
“The inflammatory response results from the hepatic release of inflammatory mediators by professional immune cells (i.e., innate, adaptive, and innate-like lymphoid cells) and nonprofessional immune cells (i.e., epithelial cells, hepatic myofibroblasts, and LSECs) that perpetuate fibrogenesis.”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [11]
In the citing paper
“Dysregulated inflammation is a characteristic feature of chronic liver diseases (CLDs), and changes in immune cell phenotype not only determine CLD progression to fibrosis/cirrhosis and the occurrence of complications but also govern CLD regression via distinct immune cell subsets (11, 12).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [11]
Citations
Cites
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
Self-citationChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Self-citationFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Research works printed but not linked: 3
- Lavine, K. et al. Targeting immune–fibroblast crosstalk in myocardial infarction and cardiac fibrosis. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-2402606/v1 (2023). Single-cell and spatial analysis of human and mouse cardiac fibrosis, defining disease-associated macrophages and changes in T cells. Identification of IL-1β+ macrophages in the fibrotic niche and demonstration that IL-1β modulation inhibits fibrosis. · DOI
- Raslan, A. A. et al. Single cell transcriptomics of fibrotic lungs unveils aging-associated alterations in endothelial and epithelial cell regeneration. Preprint at bioRxiv https://doi.org/10.1101/2023.01.17.523179 (2023). · doi:10.1101/2023.01.17.523179
- Tsukui, T. & Sheppard, D. Tracing the origin of pathologic pulmonary fibroblasts. Preprint at bioRxiv https://doi.org/10.1101/2022.11.18.517147 (2022). · doi:10.1101/2022.11.18.517147
Cited by
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Chen, Y., Wang, T., Liang, F., Han, J., Lou, Z., Yu, Y., Li, J., Zhan, T., Gu, Y., Dong, L., et al. (2024) · Theranostics · doi:10.7150/thno.94482 · Cited by 60
“Macrophages also recruit fibroblasts to form fibrotic microenvironment [10] and produce profibrotic factors to promote fibrosis [11].”
BackgroundKhanal, S., Liu, Y., Bamidele, A. O., Wixom, A. Q., Washington, A. M., Jalan-Sakrikar, N., Cooper, S. A., Vuckovic, I., Zhang, S., Zhong, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn5228 · Cited by 41
Metadata
- Authors
- Bhattacharya, M., & Ramachandran, P.
- Affiliations
- University of California, San Francisco (US)
- Centre for Inflammation Research (GB)
- Corresponding author
- Bhattacharya, Mallar
- Ramachandran, Prakash
- Venue
- Nature Immunology
- Published
- 2023-07-20
- Volume
- 24
- Issue
- 9
- Pages
- 1423-1433
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W4384923729
- Cited by
- 148
- References
- 155
- Citations by year
- 2026: 46 · 2025: 59 · 2024: 36 · 2023: 7
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH211417)
- RCUK | Medical Research Council (MR/W015919/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- fibrosis, fibrotic microenvironment, extracellular matrix deposition, fibrosis regression, antifibrotic therapy, immune profiling, chronic disease
- MeSH terms
- Extracellular Matrix, Fibrosis, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunology of human fibrosis. https://app.cochat.ai/papers/10.1038/s41590-023-01551-9
- The paper
- Bhattacharya, M., & Ramachandran, P. (2023). Immunology of human fibrosis. Nature Immunology. https://doi.org/10.1038/s41590-023-01551-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.